ArticleScientific reports2025
Association between glucose-to-lymphocyte ratio and mortality in patients with heart failure from the MIMIC-IV database: a retrospective cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Association of Admission Glucose-to-Lymphocyte Ratio With 90-Day Functional Outcome in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis.Brain and behavior · 2026Article
- Association between the glucose-to-lymphocyte ratio and prognosis in COVID-19 patients.Frontiers in cellular and infection microbiology · 2026Article
- Development and validation of a nomogram for predicting unfavorable treatment outcomes in patients with pulmonary tuberculosis and diabetes mellitus.Frontiers in medicine · 2026Article
- Association of glucose-lymphocyte ratio and short-term mortality in patients with sepsis complicated by ARDS during the acute phase: a multicenter retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glucose-to-lymphocyte ratio (GLR) has been associated with prognosis in various inflammatory diseases. However, its relationship with mortality among critically ill patients with heart failure admitted to the intensive care unit (ICU) remains poorly understood. This study aims to assess the association between GLR levels and mortality in this population and to evaluate the prognostic predictive value of GLR. This retrospective cohort study utilized data from the Medical Information Mart for Intensive Care IV (MIMIC-IV3.0) database, encompassing heart failure patients admitted between 2008 and 2022. The GLR was calculated as fasting glucose (mg/dL) divided by absolute lymphocyte count (K/µL). To evaluate the association between GLR levels and 30-day and 365-day mortality risk in heart failure patients, we employed RCS analysis, multivariable Cox regression, K-M survival curves, subgroup analyses, and ROC curves. These methods were used to assess both the prognostic relationship and the predictive accuracy of GLR. This study included a total of 14,417 patients. The association between GLR levels and all-cause mortality was found to be non-linear. In our analysis, GLR was found to be an independent predictor of both 30-day (HR 1.57, 95% CI 1.45-1.70) and 365-day mortality (HR 1.48, 95% CI 1.40-1.56). K-M survival curve analyzes showed that patients with elevated GLR levels had worse survival outcomes than patients with lower levels. Furthermore, the predictive utility of GLR appeared to exceed that of glucose or lymphocyte counts alone. GLR may be a useful tool for early identification and treatment of high-risk populations in clinical practice and may also be a potential predictor of the prognosis of patients with heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.